Skip to main content
    A

    Aurinia Pharmaceuticals Inc (AUPH)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.48
    -0.25 (-1.59%)

    Market Cap: $2.11B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Aurinia Pharmaceuticals Inc (AUPH) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Aurinia Pharmaceuticals (AUPH) trades at 15.2x trailing earnings and 6.4x sales. Its P/S of 6.4x is below its 5-year median of 6.9x. Its forward P/E is 11.3x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 34.5% higher over the next year.

    MultipleValue
    P/E (trailing)15.2x
    Forward P/E11.3x
    Price to sales6.4x
    Price to book3.1x
    EV/EBITDA12.1x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/B is 11.4% below 3.5x.

    MultipleCurrent5-year median10-year median
    P/S6.4x6.9xN/A
    P/B3.1x3.3x3.5x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 8 of the 10 year ends shown that have a P/S, its P/S ranged from 4.6x in 2022 to 866.0x in 2017.

    Year endPriceP/EP/SP/B
    2025$15.9519.7x7.7x3.8x
    2024$8.98179.6x5.5x3.5x
    2023$8.99N/A7.3x3.4x
    2022$4.32N/A4.6x1.5x
    2021$22.87N/A65.3x6.3x
    2020$13.83N/A32.7x4.0x
    2019$20.26N/AN/A6.6x
    2018$6.82N/AN/A5.2x
    2017$4.53N/A866.0x2.3x
    2016$2.10N/A433.6x3.3x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About AUPH

    What is AUPH's forward P/E ratio?

    Aurinia Pharmaceuticals has a forward P/E ratio of 11.3x.

    Is AUPH stock overvalued?

    GNG's valuation label for AUPH is Undervalued.

    What is AUPH's price to sales ratio?

    Aurinia Pharmaceuticals has a price to sales ratio of 6.4x.